CD274 and central nervous system cancer: Another ongoing phase 1 clinical trial is currently enrolling patients with IDH1-mutant gliomas that have transformed into GBM to investigate the concurrent administration of the PD-L1 inhibitor avelumab and hypofractionated radiation therapy (NCT02968940).